Related Experiment Video
Updated: May 24, 2026

Isolation of Neonatal Extrahepatic Cholangiocytes
Published on: June 5, 2014
Cholestasis in neonates with red cell alloimmune hemolytic disease: incidence, risk factors and outcome
Vivianne E H J Smits-Wintjens1, Mirjam E A Rath, Irene T M Lindenburg
1Division of Neonatology, Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands. v.smits@lumc.nl
Insights
Cholestasis affects 13% of newborns with hemolytic disease of the newborn (HDN) due to red cell alloimmunization. Intrauterine red cell transfusions (IUTs) and rhesus D alloimmunization are key risk factors for this condition.
Area of Science:
- Neonatal Medicine
- Hepatology
- Immunology
Background:
- Neonatal cholestasis in hemolytic disease of the newborn (HDN) is linked to iron overload from intrauterine red cell transfusions (IUTs).
- Limited data exists on the incidence, pathogenesis, risk factors, and outcomes of cholestasis in neonates with HDN.
Purpose of the Study:
- To determine the incidence of cholestasis in neonates with red cell alloimmune HDN.
- To identify risk factors, management strategies, and outcomes for cholestasis in this population.
Main Methods:
- Observational study of (near-) term neonates with red cell alloimmunization from 2000-2010.
- Routine liver function tests, including conjugated bilirubin, were performed.
- Risk factors, management, and outcomes were recorded for neonates with and without cholestasis.
Main Results:
- Cholestasis occurred in 13% (41/313) of neonates with red cell alloimmune HDN.
- Independent risk factors for cholestasis included at least one IUT (OR 5.81) and rhesus D alloimmunization (OR 4.66).
- Other causes of cholestasis were ruled out; supportive therapy was initiated in 5 infants, and one received iron chelation.
Conclusions:
- Cholestasis is a significant complication in 13% of neonates with HDN due to red cell alloimmunization.
- Intrauterine red cell transfusions and rhesus D alloimmunization are independently associated with the development of cholestasis.
Background:
Etiology of cholestatic liver disease in neonates with hemolytic disease of the newborn (HDN) has been associated with iron overload due to intrauterine red cell transfusions (IUTs). Data on the incidence and severity of cholestasis in neonates with HDN are scarce, and little is known about pathogenesis, risk factors, neonatal management and outcome.
Objective:
To evaluate incidence, risk factors, management and outcome of cholestasis in neonates with red cell alloimmune hemolytic disease.
Methods:
All (near-) term neonates with HDN due to red cell alloimmunization admitted to our center between January 2000 and July 2010 were included in this observational study. Liver function tests (including conjugated bilirubin) were routinely performed in the neonatal period. We recorded the presence of cholestasis, investigated several potential risk factors and evaluated the management and outcome in affected neonates.
Results:
A total of 313 infants with red cell alloimmune hemolytic disease treated with or without IUTs were included. The incidence of cholestasis was 13% (41/313). Two risk factors were independently associated with cholestasis: treatment with at least one IUT (OR 5.81, 95% CI 1.70-19.80, p = 0.005) and rhesus D type of alloimmunization (OR 4.66, 95% CI 1.05-20.57, p = 0.042). Additional diagnostic tests to investigate possible causes of cholestasis were all negative. In 5 infants (12%), supportive medical and nutritional therapy was started, and one neonate required iron chelation therapy.
Conclusion:
Cholestasis occurs in 13% of neonates with HDN due to red cell alloimmunization, and it is independently associated with IUT treatment and rhesus D type of alloimmunization.
Related Concept Videos
Rh Blood Group
Cholecystitis
Transcytosis of IgG
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
Jaundice
